1-3 of 3
David Wages, MD PhD
Close
Sort by
Journal Articles

Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML)

Mrinal M. Patnaik, MDMBBS, David A Sallman, MD, Mikkael A. Sekeres, MD MS, Selina Luger, MD FRCPC, Rafael Bejar, MD PhD, Gabriela S. Hobbs, MD, Amy E. DeZern, MD, James Bolognese, PhD, Mary Traynor, RN, Vishnu Mishra, PhD, David Wages, MD PhD, Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Eric Padron, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2963.
https://doi.org/10.1182/blood.V130.Suppl_1.2963.2963
Published: 2017
Journal Articles

Transfusion of S-303 Treated RBCs To Treat Acute Anemia during or Following Cardiac Surgery: Results of a Phase III Trial.

Richard J. Benjamin, MB CHB PhD, Jeffrey McCullough, MD, Paul D. Mintz, MD, Edward L. Snyder, MD, William D. Spotnitz, MD, David Wages, MD, PhD, Lindsey Wood, PhD, Jaime Houghton, Jin-Sying Lin, PhD, Laurence Corash, MD, Maureen G. Conlan, MD
Journal: Blood
Blood (2004) 104 (11): 381.
https://doi.org/10.1182/blood.V104.11.381.381
Published: 2004
Journal Articles

Antibody Formation to S-303-Treated RBCS in the Setting of Chronic RBC Transfusion.

Maureen G. Conlan, MD, Adonis Stassinopoulos, PhD, George Garratty, PhD, David Wages, MD, PhD, Laurence Corash, MD, Lindsey Wood, PhD, Steven R. Sloan, MD, Richard J. Labotka, MD
Journal: Blood
Blood (2004) 104 (11): 382.
https://doi.org/10.1182/blood.V104.11.382.382
Published: 2004